SCHEMBL1521409

SCHEMBL1521409

CSc1ncc2c(n1)N(C)C(=O)N(c1ccc(F)c(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.47
KDR P35968 5/20 0.41
BRAF P15056 5/20 0.40
TNK2 Q07912 2/20 0.40
MAP4K2 Q12851 2/20 0.40
GAA P10253 1/20 0.40
TRPV1 Q8NER1 3/20 0.40
BMX P51813 2/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FES P07332 1/20 0.39
RET P07949 1/20 0.39
PDGFRB P09619 1/20 0.39
KIT P10721 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39
FLT1 P17948 1/20 0.39
FGFR3 P22607 1/20 0.39
EPHA3 P29320 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521627 0.91 KDR (0.40) KDRBRAFGAATRPV1ABL1
SCHEMBL1521752 0.89 CDK8 (0.49) FGFR4KDRBRAFTNK2MAP4K2
SCHEMBL1521638 0.82 BRAF (0.47) KDRBRAFTRPV1ABL1RET
SCHEMBL1521974 0.80 CDK8 (0.47) KDRBRAFTRPV1ABL1LCK
SCHEMBL1521536 0.76 KCNJ6 (0.47) FGFR4BRAFSRC
SCHEMBL4284971 0.75 KDR (0.42) KDRBRAFTRPV1ABL1RET
SCHEMBL1521590 0.74 FGFR4 (0.42) FGFR4KDRTNK2MAP4K2BMX
SCHEMBL5057707 0.74 KDR (0.44) KDRBRAFTRPV1ABL1LCK
SCHEMBL1521723 0.74 FGFR4 (0.66) FGFR4KDRTNK2MAP4K2BMX
SCHEMBL1521801 0.73 FGFR4 (0.48) FGFR4KDRTNK2MAP4K2BMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 FGFR4 1073/4885KDR 500/4885BRAF 1/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR4 1073/4885KDR 500/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.